Most Recent Articles by Steven J. Cohen, MD
Steven J. Cohen, MD, CTA Advisory Board member highlights key science from the 2015 Gastrointestinal Cancer Symposium.
CTA Board Member Steven Cohen, MD, discusses exciting advances regarding treatment options for metastatic pancreatic cancer.
FDA approval of ramucirumab offers a new therapy option for patients with gastric cancer, which is notoriously aggressive and difficult disease to treat.
ChemotherapyAdvisor.com Editorial Board Recommends High-Impact Abstracts from the 2013 Gastrointestinal Cancers SymposiumJan 23, 2013
Dr. Steven Cohen, MD, of Fox Chase Cancer Center shares his list of recommended abstracts that will be presented at the 2013 Gastrointestinal Cancers Symposium.
Several new therapies for metastatic colorectal cancer have been developed and refined, changing the way the disease can be treated.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer